Your Article Summary
FDA approves Promacta (eltrombopag), the first oral medication to increase platelet production for people with serious blood disorder
GlaxoSmithKline, 11/21/08
GlaxoSmithKline announced that the United States Food and Drug Administration (FDA) granted accelerated approval for Promacta (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. The approval is a significant milestone for eltrombopag and the ITP community, as eltrombopag is the first oral thrombopoietin (TPO) receptor agonist approved for adult patients with chronic ITP. GSK expects eltrompopag to be available next week.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Approves Gardasil to Prevent Genital Warts in Males. Agency Also Approves Bivalent HPV Vaccine for Girls, Young Women
American Family Physician, 10/27/09
Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09
Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/09/09
Article Search
Sponsor


See Latest Articles


